Chemiluminescence Immunoassay Market Size, Share and Trends 2026 to 2035

Revenue, 2025

USD 8.37 Bn

Forecast Year, 2035

USD 17.24 Bn

CAGR, 2026 - 2035

7.49%

Report Coverage

Global

What is the Chemiluminescence Immunoassay Market Size?

The global chemiluminescence immunoassay market size is calculated at USD 8.37 billion in 2025 and is predicted to increase from USD 9.01 billion in 2026 to approximately USD 17.24 billion by 2035, expanding at a CAGR of 7.49% from 2026 to 2035.The chemiluminescence immunoassay market is experiencing significant growth due to the increasing emphasis on early disease detection. Furthermore, rising investments in drug discovery and development contributes to market expansion.

Chemiluminescence Immunoassay Market Key Takeaways

• North America held market share of 52% in 2025.
• By application, the endocrine segment is expected to captured the biggest revenue share in 2025.
• By product, the consumables segment is expected to acquire the largest share in 2025.
• By end-users, the hospitals segment registered a maximum market share in 2025.

Market Overview

Diagnostic technology is budding rapidly, and over the last decade, considerable progress has been made in the identification of antibodies, progressively impending this sort of diagnostic to that of automated clinical chemistry laboratory. The number of tests integrating chemiluminescence immunoassay analyzers practices is estimated to be magnified due to technological advancements in disease diagnosis and the upsurge in demand for treatment monitoring and precautionary diagnosis. Subsequently, the requirement for high throughput facilities is also increasing. Furthermore, large-scale laboratories are capturing the benefit of service and quality constraints confronted by small and mid-volume laboratories to seize a bigger chunk of the market by means of CLIA methods.

Companion diagnostics comprise assays or tests proposed to support healthcare providers in making treatment decisions for patients on the basis of the finest response to therapy. The co-development of companion diagnostics along with therapeutic products has the potential to meaningfully modify the drug development process and commercialize drug candidates by getting safer drugs with improved therapeutic effectiveness cost-effectively and quickly. With an increase in the demand for high-priced specialist therapies and safer drugs, the market for chemiluminescence immunoassay is expected to showcase a high growth potential.

Impact of AI on the Chemiluminescence Immunoassay Market

The integration of AI algorithms in chemiluminescence immunoassay improves the accuracy and efficiency of diagnostic processes. AI-powered advancements enhance data interpretation and decrease human errors. AI can quickly analyze vast amounts of data, providing faster and more accurate results. This allows healthcare professionals to make timely decisions. Moreover, integrating AI technologies in the manufacturing processes of CLIA automates and optimizes workflows, decreases overall operational costs, and enables high-throughput testing.

Chemiluminescence Immunoassay Market Growth Factors

• Increasing demand for accurate diagnostic tests is a major factor boosting the growth of the market.
• The rising burden of chronic diseases fuels the market growth.
• Rising research and development activities in the fields of pharmaceutical and biotechnology contribute to market expansion.
• Ongoing technological advancements led to innovations in CLIA, such as automated systems and high-throughput screening, which influence the market.
• Increasing government funding for novel drug development contributes to market growth.

Market Scope

Market Dynamics

Driver

With the rising number of cases of chronic diseases, such as cancer and diabetes, the demand for CLIA is increasing. CLIA, a powerful diagnostic technique, plays a crucial role in detecting disease patterns in patients with cancer and diabetes. The growing global population, coupled with an increase in chronic diseases, is significantly driving up the demand for these essential diagnostic tools. In response to this heightened demand, ongoing research and development in CLIA technology is fostering the innovation of new products with enhanced performance and efficiency. Innovations in this field may include improved sensitivity, which requires convenient testing to achieve accurate diagnostic tests.

Restraint

Despite their widespread use, price fluctuations influenced by geopolitical events and global economic conditions can lead to significant variations in production costs, consequently impacting the overall profitability of companies operating within the CLIA market. Furthermore, the chemiluminescence immunoassay industry is characterized by strict regulatory requirements, which can potentially increase the costs of product development, and this will cause hindrance in the market, consequently affecting the profitability of numerous players ranging from large multinational corporations to smaller regional companies vying for market share.

Opportunity

There are substantial opportunities for the growth of CLIA in the healthcare sector. The integration of CLIA with conventional drug development, particularly in areas such as chronic disease and veterinary diagnostics, presents a promising avenue for development. This holistic approach can enhance patient comfort, reduce reliance on pharmaceuticals, and improve quality of life. Continued research and development aimed at scientifically validating the efficacy and safety of CLIA also play a crucial role in addressing existing concerns. By establishing robust clinical evidence and integrating CLIA into mainstream drug development and research practices, the credibility of this natural treatment can be significantly enhanced, fostering greater acceptance and use to research and monitor therapeutic response.

Segment Insights

Regional insights

What is the U.S. Chemiluminescence Immunoassay Market Size?

The U.S. chemiluminescence immunoassay market size is exhibited at USD 3.03 billion in 2025 and is projected to be worth around USD 6.52 billion by 2035, growing at a CAGR of 7.96% from 2026 to 2035.

North America seized the substantial market stake globally in 2025 and is projected to mirror this trend during the assessment period. Significant influences backing to its governance are the existence of established healthcare infrastructure, high acceptance of cutting-edge chemiluminescence immunoassay solutions, and snowballing pervasiveness of chronic diseases among others. Additionally, augmented availability of novel CLIA systems in the U.S. on account of existence of crucial market participants like Beckman Coulter, Inc., Abbott Laboratories, Roche and DiaSorinis further likely to subsidize the growth of the market in the North America.

U.S. Chemiluminescence Immunoassay Market Trends

The U.S. market is experiencing strong growth, driven by increasing rate of chronic diseases, aging populations, and requirement for advanced, automated diagnostics with high sensitivity.

---

Asia Pacific Poised for Rapid Growth in the Chemiluminescence Immunoassay Analyzers Market

Asia Pacific is prospective to be an extremely profitable market for the chemiluminescence immunoassay analyzers market and it is anticipated to develop at a rapid growth rate throughout the estimate period. Huge population base and escalation in occurrence of infectious and chronic diseases augments requirement for diagnostic testing in the APAC. Besides, promising government initiative to progress healthcare infrastructure is expected to supplement the growth of the market.

China Chemiluminescence Immunoassay Market Analysis

China's market is experiencing robust expansion, driven by increasing chronic diseases, technological advancements, and even a shift towards advanced diagnostics, with remarkable dominance by foreign players such as Roche, though strong local firms (Snibe, Mindray, Autobio) are rapidly gaining share with affordable options, quality, focusing on high sensitivity/automation for oncology, infectious diseases, and endocrinology.

---

UK Chemiluminescence Immunoassay Market Trends

The UK chemiluminescence immunoassay market is undergoing strong growth, driven by rising chronic diseases, need for high sensitivity, and tech advances such as automation/AI, with reagents leading sales but fast growth in point-of-care along with digital integration.

---

Value Chain Analysis of Chemiluminescence Immunoassay Market

• Distribution to Hospitals, Pharmacies
  It is primarily achieved by offering high-volume testing environments, guaranteeing widespread patient access, and even integrating with established healthcare infrastructure.
• Patient Support and Services
  It focusses on improving the overall diagnostic experience and enhancing patient management and results. These services are generally offered indirectly via healthcare providers, with a rising integration of digital technologies and also at-home solutions.

Chemiluminescence Immunoassay Market Comapnies

• DiaSorin S.p.A.: DiaSorin S.p.A. is a prominent manufacturer in the chemiluminescence immunoassay (CLIA) market, providing a comprehensive portfolio of many fully automated analyzers and also a broad, specialized menu of diagnostic tests (reagents) for a broad range of clinical areas.
• Ortho Clinical Diagnostics: Ortho Clinical Diagnostics provides integrated, automated VITROS Systems for chemistry and immunoassays, aiming on high efficiency, accuracy (high first-pass yield), and also workflow optimization with a wide menu of CLIA assays for infections, cardiac markers, cancer, and more, all on a single platform, well-known for its waterless operation along with reliability in clinical labs.
  (Source:precedenceresearch.com/)

Other major Key Players

• Hoffmann-La Roche AG
• Siemens Healthineers
• Abbott Laboratories
• Immunodiagnostic Systems
• Beckman Coulter Inc.
• Inova Diagnostics, Inc.
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• Maccura Biotechnology Co., Ltd
• Others

Segments Covered in the Report